DefEYEing Expectations
ExSight Ventures Invests in DefEYE
ExSight Ventures announces its investment in DefEYE, Inc, a rapidly growing ocular company on a mission to transform and personalize therapeutic approaches in eye care. DefEYE is using decellularized placental based tissue to redefine the ocular biologics landscape with an innovative approach to both ocular surface disease and ocular surgical management.
DefEYE is focused on delivering a portfolio of innovative decellularized biologic solutions that optimize treatment and management of various eye care conditions, including ocular surface diseases, pterygium surgery, and other surgical interventions.
"ExSight's investment defies our initial skepticism of the technology and the market," said Firas Rahhal, cofounder at ExSight Ventures. "We were introduced to DefEYE's CEO through a trusted advisor, friend, and colleague. Continued conversations with ExSight's proprietary network of ophthalmologists across the nation revealed several critical factors, including better clinical outcomes, improved patient experience, and consequently, growing adoption."
The funding will enable DefEYE to accelerate commercialization through continued growth and expansion.
ExSight’s investment defies our initial skepticism of the technology and the market. We were introduced to DefEYE’s CEO through a trusted advisor, friend, and colleague. Continued conversations with ExSight’s proprietary network of ophthalmologists across the nation revealed several critical factors, including better clinical outcomes, improved patient experience, and, consequently, growing adoption.
We are not alone in our experience. Neel Desai, MD, recently shared, “I came to it with an equal amount of skepticism. What I immediately noticed was that I was getting clinical outcomes just as good — if not faster — and patients were far more comfortable.” See Dr. Desai’s full comments on DefEYE on LinkedIn.
“We work hard to find exceptional, driven, dynamic entrepreneurs at ExSight Ventures,” shared ExSight co-founder Dr. Michael Nissen. “Dr. Sambursky embodies those traits. We are happy to back Rob and DefEYE’s portfolio of decellularized ocular biologics—bringing next-generation technologies to the forefront of ophthalmic care.”
“ExSight Ventures’ deep knowledge and long-standing commitment to advancing innovation in the ophthalmic space make them an ideal strategic partner for DefEYE,” said Rob Sambursky, MD, Chief Executive Officer of DefEYE, Inc. “Their investment represents a strong validation of our vision to redefine ocular biologics through decellularized placental-based technology. Together, we are positioned to accelerate the adoption of regenerative therapies that elevate the clinical management of both ocular surface disease and ocular surgery.”
DefEYE’s stated mission to improve vision, protect the ocular surface, and improve patient quality of life aligns with the reason ExSight Ventures was founded.
Learn more about DefEYE by visiting www.defeye.com.